60 Degrees Pharmaceuticals (SXTP) Receivables (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Receivables of $335836.0 for Q1 2026, down 31.22% year-over-year from $488243.0 in Q1 2025, and down 34.1% quarter-over-quarter from $509644.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Receivables (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Receivables for 5 consecutive years, with $335836.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 31.22% year-over-year to $335836.0; the TTM figure through Mar 2026 stood at $335836.0 (down 31.22% YoY), while the FY2025 annual figure was $509644.0, up 4.7% from the prior year.
- Receivables declined to $335836.0 in Q1 2026 per SXTP's latest filing, from $509644.0 in the prior quarter.
- Across five years, Receivables topped out at $674036.0 in Q3 2025 and bottomed at $45965.0 in Q4 2022.
- Historically, Receivables has averaged $328209.9 across 5 years, with a median of $316220.0 in 2024.
- Annual changes were most pronounced in 2023 — Receivables soared 403.28% — and 2026, when it sank 31.22%.
- 60 Degrees Pharmaceuticals' Receivables stood at $45965.0 in 2022, then jumped by 403.28% to $231332.0 in 2023, then soared by 110.41% to $486748.0 in 2024, then rose by 4.7% to $509644.0 in 2025, then plunged by 34.1% to $335836.0 in 2026.
- Business Quant data shows SXTP's Receivables at $335836.0 in Q1 2026, $509644.0 in Q4 2025, and $674036.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.05 Mn | 2.03 Mn | 56,798.00 | 567,040.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,836.00 |
| Dec 31, 2025 | 509,644.00 |
| Sep 30, 2025 | 674,036.00 |
| Jun 30, 2025 | 295,034.00 |
| Mar 31, 2025 | 488,243.00 |
| Dec 31, 2024 | 486,748.00 |
| Sep 30, 2024 | 323,822.00 |
| Jun 30, 2024 | 296,370.00 |
| Mar 31, 2024 | 316,220.00 |
| Dec 31, 2023 | 231,332.00 |
| Sep 30, 2023 | 138,009.00 |
| Jun 30, 2023 | 125,470.00 |
| Dec 31, 2022 | 45,965.00 |